Low Diversity in Clinical Trial Patients & Why That's a Problem

Overprescribed

Content provided by One Scope Media. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by One Scope Media or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

6+ y ago 31:16

MP3•Episode home

Archived series ("Inactive feed" status)

When? This feed was archived on April 04, 2023 03:19 (1+ y ago). Last successful fetch was on November 14, 2022 15:01 (2y ago)

Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.

What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.

The FDA keeps approving drugs that have been tested on groups of patients that are not really diverse and this is a problem. Listen in and find out why.

Show note links:

Drug Trials Snapshots page from the FDA's website where you can learn about what these snapshots are about, how to use them, snapshot limitations and sort the table of snapshots to find the newest drugs that made the list in 2018 (so far)

2017 Drug Trials Snapshots Summary Report

2018 new drug FDA approvals mentioned in this episode:

*****BONUS links:

USA Today article on the Tuskegee Syphilis Study 45 Years Later

The FDA's press announcement (released March 2018) on the new drug approval for Trogarzo which was approved based on clinical data results of 40 patients via Fast Track, Priority Review, Breakthrough Therapy designation and Orphan Drug status

Join our private Facebook group - Consumers Unite!

28 episodes

#Science #Society #Overmedicated #Pharmaceuticalmedications #Prescriptiondrugs #One Scope Media #OTC #Pill #Prescription